Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI versus non-TBI conditioning in PTCy allogeneic hematopoietic stem cell transplantation for acute leukemia
ChiCTR2600133864Phase 2Not yet recruiting
- Sponsor
- Department of Hematology, Seventh Medical Center of Chinese PLA General Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Department of Hematology, Seventh Medical Center of Chinese PLA General Hospital. Primary endpoints: overall survival, leukemia-free survival and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2600133864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133864.